8-years PFS was 74,4%: 80,3 % for patients received adjuvant trastuzumab vs 60,9 % for patient without anti-HER treatment (p < 0,0001). Overexpression of XRCC1 was detected in 61,2% of patients and significantly correlated with poor PFS [HR = 7,181, 95% CI 2,149-24,00; p = 0,001]. Overexpression of ERCC1 was detected in 65% of patients and significantly correlated with poor PFS [HR = 2,179, 95% CI 1,123-6,581; p = 0,027] and OS [HR = 3,071, 95% CI 1,017-9,269; p = 0,047] either. Adjuvant trastuzumab therapy significantly proof PFS and OS only in ERCC1-negative patients (p = 0,008 and p = 0,009, respectively). Overexpression of XRCC1 and ERCC1 predict poor prognosis in early HER2-positive BC.